Compare Cassava Sciences Inc (FLNA) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs NICE Ltd — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while NICE Ltd trades at $117 (market cap $6.81B). The key difference: NICE Ltd is far larger — about 172.8× Cassava Sciences Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and NICE Ltd for 15 Days on average.
| FLNA | NICE | |
|---|---|---|
Market Cap | $39.40M | $6.81B |
Volume | 759,018 | 382,395 |
Sector | Health | Technology |
52-Week High | $4.64 | $137.68 |
52-Week Low | $0.68 | $83.15 |
Typical Hold Time | 37 Days | 15 Days |
Enterprise Value | -$43.28M | $6.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
NICE Ltd. (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 17.08 and strong profitability margins, including a 65.12% gross margin. Recent earnings have consistently beaten expectations, and analyst consensus is bullish with a $124.20 price target. Business developments include being named a leader in IDC MarketScape for contact center platforms, highlighting its competitive position in AI-driven customer experience solutions.
The outlook for NICE is positive, supported by AI-driven growth and a reasonable valuation. Investment opportunities include continued cloud and AI revenue expansion, while risks involve margin compression from heavy investment and market volatility. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
